Speedel pulls Swiss biotech IPO

Tough market conditions in the biotechnology sector have forced Speedel, a Swiss biopharmaceutical company, to postpone plans for an initial public offering.

The decision comes just two weeks after it scheduled a listing on the SWX Swiss Exchange for the end of May.

WSJ Logo
Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With TrumpExternal link

Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With Trump